Analyst Consensus ?
ConsensusBuy32 ratings
Bullish1546.9%
Neutral1753.1%
Bearish00.0%
Zoetis Inc. · ZTS · FY2025 Q3 · Calendar Q4 2025
Zoetis Keeps Outlook Intact as OA Pain Recovery Emerges
The supplied analysis supports a cautiously constructive view of Zoetis's operating trajectory: Simparica, international markets, livestock demand, and the innovation pipeline provide support, while OA pain adoption, clinic visits, competition, and pricing remain important constraints.
Reported Before market openNYSEHealthcare
$29.94B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.70
Consensus $1.62
EPS surprise
+4.9%
Reported versus consensus
Reported revenue
$2.40B
Consensus $2.41B
Revenue surprise
-0.4%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-13.8%
Event window
SPY move
-1.2%
Same window
Abnormal move
-12.6%
Stock minus SPY
Volume
4.2×
Versus trailing sessions
Subsequent drift
-1.5%
Up to 20 sessions
ZTSSPY benchmark
Ask FN2 about ZTS FY2025 Q3
Transcript, numbers and history already loaded
Why did ZTS fall 13.8% after beating EPS estimates in FY2025 Q3?What changed in ZTS's guidance and outlook in FY2025 Q3?Give me the bull and bear case for ZTS after FY2025 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the current analysis shows guidance maintained rather than raised, OA pain stabilizing after a decline, and additional visibility on Lenivia and Portela approvals and planned launches. Management also highlighted a leaner U.S. field structure and continued manufacturing investment.
Guidance delta
Management maintained its outlook; the supplied analysis says full-year organic revenue growth was narrowed to 5.5%–6.5% and adjusted net income growth to 5.5%–7%, with EPS guidance maintained.
Key takeaways
- Growth was led by Simparica and international markets, while the OA pain franchise showed signs of stabilization after earlier pressure.
- Management highlighted upcoming Lenivia and Portela launches, continued Librela Phase IV research, and broader pipeline progress.
- Livestock growth remained a support, linked in the analysis to protein demand and vaccine expansion.
- The main watchpoints are therapeutic veterinary-visit softness, dermatology and OA pain competition, Librela perception, and pricing or distributor dynamics.
Management priorities
- Advance Lenivia and Portela launches in 2026.
- Use Phase IV research to strengthen veterinary confidence in Librela.
- Implement a leaner, single-point-of-contact U.S. field-sales structure.
- Continue pipeline development and investment in advanced biologics manufacturing capacity.
Follow ZTS with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$71.41Previous close
$80Low
$142.67Average
$254High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 6, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| TD Cowen | Buy | Buy | Maintain | Aug 25, 2026 |
| Stifel | Hold | Hold | Maintain | Aug 20, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 11, 2026 |
| BNP Paribas | Outperform | Outperform | Maintain | Aug 11, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Aug 10, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 7, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Aug 7, 2026 |
| William Blair | Market Perform | Outperform | Downgrade | Aug 6, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 22, 2026 |
| HSBC | Buy | Buy | Maintain | Jul 6, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 1, 2026 |
| Argus Research | Hold | Buy | Downgrade | May 27, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Feb 13, 2026 |
| BTIG | Buy | Buy | Maintain | Dec 3, 2025 |
| Leerink Partners | Market Perform | Outperform | Downgrade | Jul 17, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | May 6, 2024 |
| Atlantic Equities | Overweight | Overweight | Maintain | Jun 14, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 9, 2021 |
| Raymond James | Market Perform | Outperform | Downgrade | Jul 16, 2021 |
| Truist Securities | Hold | Hold | Maintain | May 10, 2021 |
| Gabelli & Co. | Hold | Buy | Downgrade | Aug 12, 2020 |
| CFRA | Strong Buy | Buy | Upgrade | Feb 13, 2020 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | Aug 13, 2019 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jul 22, 2019 |
| Bank of America | Neutral | Buy | Downgrade | Jul 1, 2019 |
| BMO Capital | Market Perform | Market Perform | Maintain | May 9, 2019 |
| Argus | Buy | Buy | Maintain | Aug 14, 2018 |
| Deutsche Bank | Hold | Hold | Maintain | Feb 16, 2018 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Dec 15, 2016 |
| Jefferies | Buy | Buy | Maintain | Aug 4, 2016 |
| Hilliard Lyons | Neutral | Long Term Buy | Downgrade | Nov 13, 2014 |
| Edward Jones | Hold | Buy | Downgrade | Nov 12, 2014 |
Named analyst price targets
Upside is calculated against the persisted previous close $71.41. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Cantor Fitzgerald | Analyst unavailable | $94 | $77.17 | +31.6% | Aug 25, 2026 |
| Stifel Nicolaus | Jonathan Block | $80 | $76.68 | +12.0% | Aug 20, 2026 |
| Morgan Stanley | Analyst unavailable | $85 | $75.3 | +19.0% | Aug 7, 2026 |
| UBS | Analyst unavailable | $85 | $76.52 | +19.0% | Jul 27, 2026 |
| Morgan Stanley | Analyst unavailable | $99 | $75.5 | +38.6% | Jul 22, 2026 |
| HSBC | Analyst unavailable | $95 | $74.63 | +33.0% | Jul 6, 2026 |
| Barclays | Analyst unavailable | $85 | $71.91 | +19.0% | Jul 1, 2026 |
| Stifel Nicolaus | Analyst unavailable | $85 | $77.82 | +19.0% | Jun 26, 2026 |
| Stifel Nicolaus | Analyst unavailable | $95 | $80.06 | +33.0% | May 22, 2026 |
| Morgan Stanley | Erin Wright | $115 | $76.06 | +61.0% | May 15, 2026 |
| UBS | Analyst unavailable | $99 | $83.27 | +38.6% | May 8, 2026 |
| Stifel Nicolaus | Analyst unavailable | $105 | $87.31 | +47.0% | May 8, 2026 |
| UBS | Analyst unavailable | $130 | $116.71 | +82.0% | Apr 28, 2026 |
| BTIG | Mark Massaro | $160 | $128.95 | +124.1% | Feb 26, 2026 |
| UBS | Analyst unavailable | $136 | $122.75 | +90.4% | Jan 29, 2026 |
| Piper Sandler | David Westenberg | $135 | $125.08 | +89.0% | Jan 22, 2026 |
| Morgan Stanley | Analyst unavailable | $160 | $124.54 | +124.1% | Dec 18, 2025 |
| HSBC | Analyst unavailable | $140 | $115.75 | +96.1% | Dec 10, 2025 |
| Barclays | Analyst unavailable | $136 | $118.16 | +90.4% | Dec 8, 2025 |
| Stifel Nicolaus | Analyst unavailable | $140 | $125.5 | +96.1% | Nov 4, 2025 |
| UBS | Analyst unavailable | $158 | $144.9 | +121.3% | Oct 20, 2025 |
| Piper Sandler | David Westenberg | $215 | $148.86 | +201.1% | Aug 11, 2025 |
| Stifel Nicolaus | Jonathan Block | $160 | $161.67 | +124.1% | Jun 17, 2025 |
| UBS | Andrea Alfonso | $170 | $149.87 | +138.1% | May 7, 2025 |
| Stifel Nicolaus | Jonathan Block | $165 | $150.83 | +131.1% | Apr 14, 2025 |
| Morgan Stanley | Erin Wright | $243 | $172.24 | +240.3% | Feb 4, 2025 |
| Barclays | Balaji Prasad | $242 | $185.29 | +238.9% | Aug 7, 2024 |
| Stifel Nicolaus | Jonathan Block | $200 | $176.31 | +180.1% | Aug 5, 2024 |
| Piper Sandler | David Westenberg | $195 | $149.77 | +173.1% | Apr 16, 2024 |
| Stifel Nicolaus | Jonathan Block | $195 | $167.02 | +173.1% | Apr 2, 2024 |
| Morgan Stanley | Analyst unavailable | $248 | $150.25 | +247.3% | Nov 15, 2022 |
| Jefferies | David Steinberg | $254 | $191.32 | +255.7% | Feb 21, 2022 |
| Argus Research | Jasper Hellweg | $225 | $203.86 | +215.1% | Aug 25, 2021 |
| Credit Suisse | Katie Tryhane | $230 | $199.16 | +222.1% | Aug 9, 2021 |
Track every rating change on ZTS the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationZoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology.…
Historical context
All ZTS earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
- ACNFY2026 Q4 · October 1, 2026+3.5% EPS+15.8% move
- MKCFY2026 Q3 · October 1, 2026+13.9% EPS-4.9% move
- NKEFY2027 Q1 · October 1, 2026+10.0% EPS-0.7% move
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
- FDSFY2026 Q4 · September 30, 2026+3.9% EPS+3.8% move
- JBLFY2026 Q4 · September 30, 2026+8.1% EPS-10.0% move
Get the ZTS recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-10-06T09:00:42.474755+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-06T09:00:42.471690+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-06. For educational purposes only; not investment advice.